Q3 2026 Humana Inc. Earnings Conference Call - HUMANA INC

Financial Performance:

• Full-year adjusted EPS outlook increased to at least $9.50 (previously at least $9.00) driven by cost trends beating expectations and Part D favorability.
• Individual MA pre-tax margins are on track to double this year, excluding STARS headwinds, moving from near break-even to above break-even.
• Benefit reserves are maintained prudently with IB&R rising sequentially despite seasonal shifts; pharmacy costs remain a significant portion of total benefit costs.
• Expected to reduce debt-to-cap ratio by approximately 130 basis points in Q4 following the BlackRock JV and Gentiva divestiture.
• BlackRock JV transaction is expected to reduce JV-related liabilities on the balance sheet due to significantly lower cost of capital.
• Divestment of minority interest in Gentiva closing this quarter with ~$900 million in pre-tax proceeds.

Guidance and Future Outlook:

• Long-term goal remains a 3%+ MA margin in 2028, now viewed as achievable and potentially ahead of plan.
• 2028 is expected to generate a one-time tailwind due to STARS performance exceeding top-quartile targets; management plans to invest part of this and pass the remainder to shareholders.
• Full-year 2027 membership growth is anticipated based on strong AEP performance, though specific percentage guidance is deferred until retention data is available.
• 2027 cost trend guidance raised to 8-9% (up from 7-8%) due to a robust health technology pipeline, with Part D expected to rise 14-15%.
• 2028 STARS performance is the primary catalyst for margin expansion, though exact EPS quantification of the tailwind will be provided in late 2027 or Q4 2027.

Business Segments and Product Lines:

• Medicare Advantage: 2026 membership performing in line to better than expected; 2027 product positioning on track for margin progression.
• Star Ratings: Bonus Year 2028 (BY28) member-weighted star rating reached 4.17, the highest in company history, exceeding the top-quartile threshold.
• Clinical Excellence: BY28 results delivered 663,000 additional care opportunities, including 600 previously undetected breast cancers and 17,000 diabetes-related eye disease diagnoses.
• Medicaid: Membership grew by 104,000 in 2026; footprint expanded to 13 states (11 active) with pending contracts in Georgia and Texas.
• CenterWell Primary Care: Added nearly 147,000 members (30% growth) including the MaxHealth acquisition; new partnership established with BlackRock.
• PCO (Primary Care Organizations): Addressed cost pressure in one Florida geography through improved contracting and network management; enterprise impact deemed not meaningful.

Market and Competitive Landscape:

• Competitive dynamics in 2027 show improved positioning for major players due to consolidation of smaller plans and fewer plan exits.
• Growth drivers include strong performance from distribution channel partners (brokers) and high retention of members from exited plans.
• Market share gains are anticipated from improved product pricing and quality positioning rather than aggressive growth at the expense of margins.
• Reinsurance usage remains stable with primary focus on capital efficiency in insurance subsidiaries rather than significant increases in 2027.

Risks and Challenges:

• Part D cost trends driven by the health technology pipeline are a key financial headwind for 2027, necessitating pricing adjustments.
• STARS-related revenue volatility requires disciplined cost and benefit structure management based on a top-quartile threshold rather than best-case scenarios.
• Specific cost pressure in one PCO geography (Florida) required corrective action with payers to stabilize margins.
• Future margin expansion is dependent on the successful execution of cost transformation and the eventual reduction of the STARS headwind by 2028.

Management Commentary and Tone:

• Tone is highly confident and positive, emphasizing "strong execution," "tangible results," and being "ahead of plan."
• Management framed the strategy around four drivers: product/experience, clinical excellence, efficient operations, and capital allocation.
• CEO Jim Recton highlighted "operational discipline" as a core philosophy, managing the business to a sustainable top-quartile STARS baseline while targeting outperformance.
• CFO Celeste Millay emphasized balance sheet efficiency, noting reduced debt-to-cap ratios and increased financial flexibility as key wins.
• Management stressed that the 2028 tailwind is a result of current overperformance and will be managed with discipline regarding reinvestment vs. shareholder returns.

Analyst Questions and Answers:

• 2027 Margin Drivers: Management cited pricing initiatives, operational cost transformation, and fewer new member headwinds as key margin drivers, with no incremental headwinds beyond the current STARS headwind.
• 2028 STARS Tailwind: Management clarified that the 2028 target is top-quartile; any earnings above this threshold (tailwind) will be split between reinvestment and shareholder returns, but exact numbers are not available until late next year.
• Capital Allocation: Largest capital use is funding insurance reserves for growth; future M&A and organic growth will focus on Medicaid and CenterWell. Share buybacks are viewed as "onerous" to debt-to-cap; dividend growth is prioritized once payout ratios normalize.
• Reinsurance Strategy: Reinsurance usage is optimized for capital efficiency (subsidiary funding) and is not expected to change substantially in 2027.
• STARS Philosophy: Shifted from targeting 90% 4-star plans to managing to a top-quartile cost baseline to ensure sustainable margin discipline, while still aiming for outperformance.
• Provider Relationships: Increased focus on high-quality providers regardless of risk participation; value-based care percentage remains stable but governance is strengthened.

Other Key Points:

• Upcoming December 10th investor event will provide detailed updates on 2028 commitments, the STARS tailwind quantification, and the margin expansion roadmap.
• 65,000 associates contributed to the clinical outcomes and Star rating success, with specific examples of early cancer and disease detection.
• The BlackRock JV replaces previous Welsh Carson arrangements, providing a put option for BlackRock and a call option for Humana to purchase clinics starting in 2028.
• Group MA business improved 500 basis points in margins (excluding STARS) due to recontracting efforts, though full benefits lag until STARS stabilizes.